Bulk Inquiry
CPI-613
- Devimistat - 6,8-Bis(benzylthio)octanoic acid
Axon 2125
CAS:
95809-78-2
Purity:
100%
- Soluble in 0.1N NaOH(aq) and DMSO
- MF: C22H28O2S2
- MW: 388.59
Description
CPI-613 (Devimistat) is a lipoate analogue anticancer metabolism modulator that targets mitochondrial enzyme complexes, including pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase. It disrupts mitochondrial energy metabolism and TCA-cycle dependent tumor cell survival.
Mitochondrial metabolic plasticity is central to cancer bioenergetics, redox homeostasis and therapeutic resistance. CPI-613 is relevant for studying mitochondrial enzyme targeting and metabolic vulnerabilities in tumor models.
Key Features
- Targets mitochondrial energy metabolism
- Modulates PDH and α-ketoglutarate dehydrogenase pathways
- Disrupts TCA-cycle-dependent tumor cell survival
- Clinically relevant cancer metabolism scaffold
Applications
- Cancer metabolism research
- Mitochondrial enzyme pathway studies
- PDH and TCA cycle assays
- Metabolic vulnerability profiling in oncology models
More Information
| Parent CAS No. | 95809-78-2 |
|---|---|
| Chemical Name | 6,8-Bis(benzylthio)octanoic acid |
| SMILES | C(O)(=O)CCCCC(SCC1=CC=CC=C1)CCSCC1=CC=CC=C1 |
| MFCD | N.A. |
| InChi | InChI=1S/C22H28O2S2/c23-22(24)14-8-7-13-21(26-18-20-11-5-2-6-12-20)15-16-25-17-19-9-3-1-4-10-19/h1-6,9-12,21H,7-8,13-18H2,(H,23,24) |
| InChiKey | ZYRLHJIMTROTBO-UHFFFAOYSA-N |
| CID | 24770514 |
| Short Description | PDH inhibitor |
References
- Z Zachar et al. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. J. Mol. Med. (Berl). 2011, 89(11), 1137-1148.
- KC Lee et al. Formation and anti-tumor activity of uncommon in vitro and in vivo metabolites of CPI-613, a novel anti-tumor compound that selectively alters tumor energy metabolism. Drug Metab. Lett. 2011, 5(3), 163-182.
Other Categories
Get a Quote for
Loading...